In the first half of 2025, King Faisal Specialist Hospital and Research Centre (KFSH) made significant strides in clinical research by conducting 48% of all clinical trials registered in Saudi Arabia. This achievement underscores the hospital’s expanding influence in the realms of clinical research and advanced healthcare development. The hospital’s clinical research is supported by a robust team of investigators, research nurses, pharmacists, coordinators, data specialists, and regulatory and ethics teams, all of whom play a crucial role in transitioning clinical studies from the initial planning phases through to patient recruitment, trial execution, safety monitoring, and data management.
Originally established in 2020, KFSH’s centralized Clinical Trials service was designed to streamline research activities conducted by its clinicians and investigators. This service is instrumental in supporting various phases of clinical trials, including feasibility assessments, study activation, trial operations, and patient recruitment. It also manages investigational medicines, data quality, safety reporting, and adherence to regulatory and ethical standards. By the midpoint of 2025, KFSH had 104 active clinical trials and was initiating 80 new studies across diverse medical fields such as cancer, cardiovascular disease, autoimmune and musculoskeletal conditions, dermatology, gastroenterology, liver disease, and endocrine and metabolic disorders. These studies not only provide patients with complex conditions access to innovative treatment options but also generate vital clinical evidence tailored to the healthcare needs of Saudi Arabia.
A key milestone in KFSH’s research endeavors was the commencement of a Phase I clinical trial involving locally manufactured genetically engineered CAR-T cells for the treatment of relapsed acute lymphoblastic leukemia. This trial is a testament to the hospital’s ability to integrate local scientific expertise, advanced biomanufacturing capabilities, and specialized clinical care within a cohesive research framework. This development highlights KFSH’s commitment to advancing cell therapy research and offering new hope for patients with challenging medical conditions.
KFSH’s centralized clinical-trial infrastructure also facilitates its participation in complex international studies. The hospital’s research governance, coupled with its specialized clinical capabilities, lays a solid foundation for collaboration with multinational research partners. This collaboration ensures that the hospital maintains high standards of patient safety, ethics, data quality, and regulatory compliance. The hospital plans to showcase its innovative approach to clinical research and healthcare at the upcoming C3 US NYC Davos of Healthcare Summit 2026 in New York City on September 14.
King Faisal Specialist Hospital and Research Centre, located in Riyadh, Saudi Arabia, has garnered recognition as one of the leading academic medical centers globally and within the Middle East. Its reputation is further bolstered by its inclusion in international hospital rankings and acknowledgment as a prominent healthcare brand.
Legal Disclaimer:
The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.